Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist

European Journal of Pharmacology

Volumn 761, Issue , 2015, Pages 226-234

  Arai, Kiyoshi ^a   Homma, Tsuyoshi ^a   Morikawa, Yuka ^a   Ubukata, Naoko ^a   Tsuruoka, Hiyoyuki ^a   Aoki, Kazumasa ^a   Ishikawa, Hirokazu ^a   Mizuno, Makoto ^a   Sada, Toshio ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Aldosterone; CS 3150; Mineralocorticoid receptor antagonist; Urinary Na+ K+ ratio

Indexed keywords

1 (2 HYDROXYETHYL) 4 METHYL N [4 (METHYLSULFONYL)PHENYL] 5 [2 (TRIFLUOROMETHYL)PHENYL] 1H PYRROLE 3 CARBOXAMIDE; ALDOSTERONE; ANDROGEN RECEPTOR; DEOXYCORTICOSTERONE ACETATE; EPLERENONE; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; POTASSIUM; PROGESTERONE RECEPTOR; SODIUM; SPIRONOLACTONE; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; CS-3150; NR3C2 PROTEIN, HUMAN; PROTEIN BINDING; PYRROLE DERIVATIVE; SULFONE; URINARY TRACT AGENT;

ADRENALECTOMY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ELEVATED BLOOD PRESSURE; FEMALE; IC50; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA HALF LIFE; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RAT; SALT LOADING; SINGLE DRUG DOSE; SODIUM URINE LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSCRIPTION INITIATION; ANALOGS AND DERIVATIVES; ANIMAL; BINDING COMPETITION; BLOOD PRESSURE; CHEMICALLY INDUCED; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ELECTROLYTE BALANCE; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HUMAN; HYPERTENSION; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RABBIT; RADIOASSAY; SPRAGUE DAWLEY RAT; URINE; WISTAR KYOTO RAT;

ADMINISTRATION, ORAL; ADRENALECTOMY; ALDOSTERONE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BINDING, COMPETITIVE; BLOOD PRESSURE; DESOXYCORTICOSTERONE ACETATE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEK293 CELLS; HUMANS; HYPERTENSION; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POTASSIUM; PROTEIN BINDING; PYRROLES; RABBITS; RADIOLIGAND ASSAY; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; SODIUM; SPIRONOLACTONE; SULFONES; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; UROLOGICAL AGENTS; WATER-ELECTROLYTE BALANCE;

EID: 84935872611     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.06.015     Document Type: Article

References (43)

1. Asoh, Y., Tsuruoka, H., Hayashi, N., Yoshida, J., Aoki, K., Homma, T., Arai, K., in preparation. Discovery of novel atropisomerism in CS-3150 as a potent non-steroidal mineralocorticoid receptor antagonist. Unpublished results.
2. L. Bärfacker, A. Kuhl, A. Hillisch, R. Grosser, S. Figueroa-Pérez, H. Heckroth, A. Nitsche, J.K. Ergüden, H. Gielen-Haertwig, K.H. Schlemmer, J. Mittendorf, H. Paulsen, J. Platzek, and P. Kolkhof Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases ChemMedChem 7 2012 1385 1403
3. Canne, B.L., Chen, J., Dalrymple, L.E., Flatt, B.T., Forsyth, T.P., Gu, X.H., Mac, M.B., Mann, L.W., Mann, G., Martin, R., Mohan, R., Murphy, B., Nyman, M.C., Stevens, W.C., Jr., Wang, T.L., Wong, Y., Wu, J.H., 2006. WO Patent no. WO2006/012642.
4. A. Casimiro-Garcia, D.W. Piotrowski, C. Ambler, G.B. Arhancet, M.E. Banker, T. Banks, C.M. Boustany-Kari, C. Cai, X. Chen, R. Eudy, D. Hepworth, C.A. Hulford, S.M. Jennings, P.M. Loria, M.J. Meyers, D.N. Petersen, N.K. Raheja, M. Sammons, L. She, K. Song, D. Vrieze, and L. Wei Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist J. Med. Chem. 57 2014 4273 4288
5. C. Catena, G. Colussi, E. Nadalini, A. Chiuch, S. Baroselli, R. Lapenna, and L.A. Sechi Cardiovascular outcomes in patients with primary aldosteronism after treatment Arch. Intern. Med. 168 2008 80 85
6. 14C] eplerenone after oral administration to humans Drug Metab. Dispos. 31 2003 1448 1455
7. C.S. Cook, L. Zhang, G.B. Ames, J. Fischer, J. Zhang, and S. Levin Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats Xenobiotica 33 2003 305 321
8. P. Corvol, J.A. Mahoudeau, J.C. Valcke, J. Ménard, and H. Bricaire Sexual side-effects of spironolactones. Possible mechanisms of their anti-androgen action Nouv. Presse Med. 5 1976 691 694
9. J.M. Cox, H.D. Chu, C. Yang, H.C. Shen, Z. Wu, J. Balsells, A. Crespo, P. Brown, B. Zamlynny, J. Wiltsie, J. Clemas, J. Gibson, L. Contino, J. Lisnock, G. Zhou, M. Garcia-Calvo, T. Bateman, L. Xu, X. Tong, M. Crook, and P. Sinclair Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series Bioorg. Med. Chem. Lett 24 2014 1681 1684
10. M. de Gasparo, S.E. Whitebread, G. Preiswerk, X. Jeunemaître, P. Corvol, and J. Ménard Antialdosterones: incidence and prevention of sexual side effects J. Steroid Biochem. 32 1989 223 227
11. J.A. Delyani, R. Rocha, C.S. Cook, D.S. Tobert, S. Levin, B. Roniker, D.L. Workman, Y.L. Sing, and B. Whelihan Eplerenone: a selective aldosterone receptor antagonist (SARA) Cardiovasc. Drug Rev. 19 2001 185 200
12. M. Epstein, G.H. Williams, M. Weinberger, A. Lewin, S. Krause, R. Mukherjee, R. Patni, and B. Beckerman Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes Clin. J. Am. Soc. Nephrol. 1 2006 940 951
13. A. Fiebeler, and F.C. Luft The mineralocorticoid receptor and oxidative stress Heart Fail. Rev. 10 2005 47 52
14. Y. Furumatsu, Y. Nagasawa, K. Tomida, S. Mikami, T. Kaneko, N. Okada, Y. Tsubakihara, E. Imai, and T. Shoji Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker Hypertens. Res. 31 2008 59 67
15. S.M. Garthwaite, and E.G. McMahon The evolution of aldosterone antagonists Mol. Cell. Endocrinol. 31 2004 27 31
16. K.C. Gilbert, and N.J. Brown Aldosterone and inflammation Curr. Opin. Endocrinol. Diabetes Obes. 17 2010 199 204
17. X. Jeunemaitre, G. Chatellier, C. Kreft-Jais, A. Charru, C. DeVries, P.F. Plouin, P. Corvol, and J. Menard Efficacy and tolerance of spironolactone in essential hypertension Am. J. Cardiol. 60 1987 820 825
18. A.M. Kaukonen, H. Lennernäs, and J.P. Mannermaa Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats J. Pharm. Pharmacol. 50 1998 611 619
19. K. Kikkawa Revisiting the therapeutic concept of a mineralocorticoid receptor antagonist-focusing on resistant hypertension and chronic renal failure (Article in Japanese) Nihon Yakurigaku Zasshi 139 2012 241 245
20. B. Klanke, N. Cordasic, A. Hartner, R.E. Schmieder, R. Veelken, and K.F. Hilgers Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension Nephrol. Dial. Transplant. 23 2008 3456 3463
21. M. Lombès, N. Alfaidy, E. Eugene, A. Lessana, N. Farman, and J.P. Bonvalet Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart Circulation 92 1995 175 182
22. J.M. Luther Is there a new dawn for selective mineralocorticoid receptor antagonism? Curr. Opin. Nephrol. Hypertens. 23 2014 456 461
23. D. Marver, and J.P. Kokko Renal target sites and the mechanism of action of aldosterone Miner. Electrolyte Metab. 9 1983 1 18
24. P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, and J.J. Mourad Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J. Am. Coll. Cardiol. 45 2005 1243 1248
25. + and K J. Am. Soc. Nephrol. 14 2003 1107 1115
26. + excretion activity J. Pharmacol. Sci. 115 2011 346 353
27. T. Nariai, K. Fujita, M. Mori, S. Katayama, S. Hori, and K. Matsui SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats J. Cardiovasc. Pharmacol. 59 2012 458 464
28. A. Nishiyama, L. Yao, Y. Fan, M. Kyaw, N. Kataoka, K. Hashimoto, Y. Nagai, E. Nakamura, M. Yoshizumi, T. Shokoji, S. Kimura, H. Kiyomoto, K. Tsujioka, M. Kohno, T. Tamaki, F. Kajiya, and Y. Abe Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability Hypertension 45 2005 710 716
29. J. Ouzan, C. Pérault, A.M. Lincoff, E. Carré, and M. Mertes The role of spironolactone in the treatment of patients with refractory hypertension Am. J. Hypertens. 15 2002 333 339
30. D.W. Piotrowski Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy J. Med. Chem. 55 2012 7957 7966
31. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, and M. Gatlin Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctions N. Engl. J. Med. 348 2003 1309 1321
32. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, and J. Wittes The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators N. Engl. J. Med. 341 1999 709 717
33. L.I. Rose, R.H. Underwood, S.R. Newmark, E.S. Kisch, and G.H. Williams Pathophysiology of spironolactone-induced gynecomastia Ann. Intern. Med. 87 1977 398 403
34. K. Rossing, K.J. Schjoedt, U.M. Smidt, F. Boomsma, and H.H. Parving Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study Diabetes Care 28 2005 2106 2112
35. T. Saruta, S. Kageyama, T. Ogihara, K. Hiwada, M. Ogawa, K. Tawara, M. Gatlin, S. Garthwaite, R. Bittman, and J. Patrick Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled dose-ranging study J. Clin. Hypertens. 6 2004 175 183
36. S. Shibata, M. Nagase, S. Yoshida, H. Kawachi, and T. Fujita Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1 Hypertension 49 2007 355 364
37. D.A. Sica Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis Heart Fail. Rev. 10 2005 23 29
38. R. Takeda, H. Hatakeyama, Y. Takeda, K. Iki, I. Miyamori, W.P. Sheng, H. Yamamoto, and I.A. Blair Aldosterone biosynthesis and action in vascular cells Steroids 60 1995 120 124
39. M. Watzka, S. Beyenburg, I. Blümcke, C.E. Elger, F. Bidlingmaier, and B. Stoffel-Wagner Expression of mineralocorticoid and glucocorticoid receptor mRNA in the human hippocampus Neurosci. Lett. 290 2000 121 124
40. M.H. Weinberger, B. Roniker, S.L. Krause, and R.J. Weiss Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension Am. J. Hypertens. 15 2002 709 716
41. M.J. Young Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation Curr. Opin. Nephrol. Hypertens. 17 2008 174 180
42. F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, S.J. Pocock, and B. Pitt Eplerenone in patients with systolic heart failure and mild symptoms N. Engl. J. Med. 364 2011 11 21
43. M.C. Zennaro, D. Le Menuet, S. Viengchareun, F. Walker, D. Ricquier, and M. Lombès Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action J. Clin. Investig. 101 1998 1254 1260